NO20015228L - Anvendelse av saredutant og de farmasöytisk aksepterbare salter derav for fremstilling av medikamenter anvendt for åbehandle eller forebygge sinnslidelser, tilpasningslidelser ellerblandede angst-depresjonslidelser - Google Patents

Anvendelse av saredutant og de farmasöytisk aksepterbare salter derav for fremstilling av medikamenter anvendt for åbehandle eller forebygge sinnslidelser, tilpasningslidelser ellerblandede angst-depresjonslidelser

Info

Publication number
NO20015228L
NO20015228L NO20015228A NO20015228A NO20015228L NO 20015228 L NO20015228 L NO 20015228L NO 20015228 A NO20015228 A NO 20015228A NO 20015228 A NO20015228 A NO 20015228A NO 20015228 L NO20015228 L NO 20015228L
Authority
NO
Norway
Prior art keywords
disorders
saredutant
treat
manufacture
pharmaceutically acceptable
Prior art date
Application number
NO20015228A
Other languages
English (en)
Norwegian (no)
Other versions
NO20015228D0 (no
Inventor
Xavier Emonds-Alt
Philippe Soubrie
Regis Steinberg
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of NO20015228D0 publication Critical patent/NO20015228D0/no
Publication of NO20015228L publication Critical patent/NO20015228L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
NO20015228A 1999-04-27 2001-10-25 Anvendelse av saredutant og de farmasöytisk aksepterbare salter derav for fremstilling av medikamenter anvendt for åbehandle eller forebygge sinnslidelser, tilpasningslidelser ellerblandede angst-depresjonslidelser NO20015228L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9905338A FR2792835B3 (fr) 1999-04-27 1999-04-27 Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression
PCT/FR2000/001084 WO2000064423A2 (fr) 1999-04-27 2000-04-25 Utilisation du saredutant et de ses sels pharmaceutiquement acceptables dans le traitement ou la prevention des troubles de l'humeur d'adaptation et de l'anxiete-depression

Publications (2)

Publication Number Publication Date
NO20015228D0 NO20015228D0 (no) 2001-10-25
NO20015228L true NO20015228L (no) 2001-12-21

Family

ID=9544931

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015228A NO20015228L (no) 1999-04-27 2001-10-25 Anvendelse av saredutant og de farmasöytisk aksepterbare salter derav for fremstilling av medikamenter anvendt for åbehandle eller forebygge sinnslidelser, tilpasningslidelser ellerblandede angst-depresjonslidelser

Country Status (33)

Country Link
US (3) US6573281B1 (cs)
EP (1) EP1173179B1 (cs)
JP (1) JP2002542281A (cs)
KR (1) KR20020001850A (cs)
CN (1) CN1172669C (cs)
AR (1) AR023597A1 (cs)
AT (1) ATE234617T1 (cs)
AU (1) AU764304B2 (cs)
BG (1) BG65472B1 (cs)
BR (1) BR0010006A (cs)
CA (1) CA2370834C (cs)
CZ (1) CZ294904B6 (cs)
DE (1) DE60001725T2 (cs)
DK (1) DK1173179T3 (cs)
EE (1) EE05211B1 (cs)
ES (1) ES2193065T3 (cs)
FR (1) FR2792835B3 (cs)
HK (1) HK1041821A1 (cs)
HU (1) HUP0200969A3 (cs)
IL (1) IL145269A0 (cs)
MX (1) MXPA01010904A (cs)
NO (1) NO20015228L (cs)
NZ (1) NZ513851A (cs)
PL (1) PL196479B1 (cs)
PT (1) PT1173179E (cs)
RU (1) RU2238726C2 (cs)
SI (1) SI1173179T1 (cs)
SK (1) SK285459B6 (cs)
TR (1) TR200102512T2 (cs)
TW (1) TWI225399B (cs)
UA (1) UA69441C2 (cs)
WO (1) WO2000064423A2 (cs)
ZA (1) ZA200107143B (cs)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2792835B3 (fr) * 1999-04-27 2001-05-25 Sanofi Sa Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression
WO2001077069A1 (en) * 2000-04-06 2001-10-18 Astrazeneca Ab Naphthamide neurokinin antagonists for use as medicaments
US6903092B2 (en) 2000-04-06 2005-06-07 Peter Bernstein Naphthamide neurokinin antagonists for use as medicaments
ATE400563T1 (de) * 2000-04-06 2008-07-15 Astrazeneca Ab Neue neurokinin-antagonisten zum gebrauch als arzneimittel
US6846814B2 (en) 2000-04-06 2005-01-25 Astra Zeneca Ab Neurokinin antagonists for use as medicaments
GB0019008D0 (en) * 2000-08-04 2000-09-27 Astrazeneca Ab Therapeutic compounds
SE0003476D0 (sv) * 2000-09-28 2000-09-28 Astrazeneca Ab Compounds
FR2904221B1 (fr) * 2006-07-31 2008-09-12 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et la fluoxetine.
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
FR2912058A1 (fr) * 2007-02-07 2008-08-08 Sanofi Aventis Sa Utilisation d'un compose antagoniste des recepteurs nk2 de la neurokinine a pour la preparation de medicaments utiles pour la prevention et le traitement des dysfonctions sexuelles
JP2010539126A (ja) * 2007-09-14 2010-12-16 エフ．ホフマン−ラ ロシュ アーゲー Ｎｋ３受容体アンタゴニストとしてのピペリジン誘導体
US20090076083A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched saredutant

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99320A (en) * 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical preparations containing them
FR2695626B1 (fr) * 1992-09-17 1994-12-02 Lebroch Yannick Dispositif de gobelet adaptable sur un conteneur de boisson.
FR2700472B1 (fr) 1993-01-19 1995-02-17 Rhone Poulenc Rorer Sa Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
US5512680A (en) * 1993-02-26 1996-04-30 Sanofi Process for the preparation of an optically pure aminoalcohol
TW385308B (en) * 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5554644A (en) * 1994-06-08 1996-09-10 Warner-Lambert Company Tachykinin (NK2) antagonists
FR2792835B3 (fr) * 1999-04-27 2001-05-25 Sanofi Sa Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression

Also Published As

Publication number Publication date
AU764304B2 (en) 2003-08-14
DE60001725D1 (de) 2003-04-24
PT1173179E (pt) 2003-06-30
CZ294904B6 (cs) 2005-04-13
MXPA01010904A (es) 2002-06-21
CA2370834C (en) 2007-09-25
SI1173179T1 (en) 2003-06-30
ZA200107143B (en) 2002-10-30
SK285459B6 (sk) 2007-02-01
US7390823B2 (en) 2008-06-24
CN1172669C (zh) 2004-10-27
EP1173179B1 (fr) 2003-03-19
KR20020001850A (ko) 2002-01-09
RU2238726C2 (ru) 2004-10-27
BR0010006A (pt) 2002-01-15
TR200102512T2 (tr) 2002-04-22
EP1173179A2 (fr) 2002-01-23
JP2002542281A (ja) 2002-12-10
EE05211B1 (et) 2009-10-15
ES2193065T3 (es) 2003-11-01
ATE234617T1 (de) 2003-04-15
AU4303400A (en) 2000-11-10
PL196479B1 (pl) 2008-01-31
HK1041821A1 (en) 2002-07-26
US20030176462A1 (en) 2003-09-18
US6573281B1 (en) 2003-06-03
HUP0200969A3 (en) 2004-03-01
SK15472001A3 (sk) 2002-03-05
EE200100553A (et) 2003-02-17
WO2000064423A3 (fr) 2001-04-19
BG65472B1 (bg) 2008-09-30
IL145269A0 (en) 2002-06-30
BG105962A (en) 2002-05-31
FR2792835B3 (fr) 2001-05-25
CN1348371A (zh) 2002-05-08
NO20015228D0 (no) 2001-10-25
NZ513851A (en) 2003-04-29
WO2000064423A2 (fr) 2000-11-02
TWI225399B (en) 2004-12-21
CA2370834A1 (en) 2000-11-02
PL351922A1 (en) 2003-06-30
US20080227818A1 (en) 2008-09-18
HUP0200969A2 (hu) 2002-07-29
DE60001725T2 (de) 2004-02-05
UA69441C2 (uk) 2004-09-15
DK1173179T3 (da) 2003-07-14
AR023597A1 (es) 2002-09-04
CZ20013812A3 (cs) 2002-02-13
FR2792835A1 (fr) 2000-11-03

Similar Documents

Publication Publication Date Title
NO20022585L (no) Pyrrolidinacetamidderivat alene eller i kombinasjon for behandling av forstyrrelser i sentralnervesystemet
IL163102A (en) Dihydrobenzodiazepin-2-one derivatives, process for their preparation and use thereof in the preparation of medicaments for the treatment of neurological disorders
NO20021845D0 (no) Behandling av sövnforstyrrelser under anvendelse av desloratadin
NO20015228D0 (no) Anvendelse av saredutant og de farmasöytisk aksepterbare salter derav for fremstilling av medikamenter anvendt for åbehandle eller forebygge sinnslidelser, tilpasningslidelser ellerblandede angst-depresjonslidelser
WO2003015779A3 (de) Matrixkontrolliertes transdermales therapeutisches system zur anwendung von pramipexol und ropinirol
IL127943A0 (en) Pharmaceutical and cosmetic composition for the treatment of skin disorders
NO20031903L (no) Nye amidoalkylpiperidin- og amidoalkylpiperazinderivater for anvendelse vedbehandling av nervesystemlidelser
EE04497B1 (et) Püridopüranoasepiini derivaadid, nende valmistamine ja terapeutiline kasutamine
NO20022021D0 (no) Indeno-, nafto- og benzocyklohepta-dihydrotiazolderivater, fremstilling av de samme og deres anvendelse somanoreksilegemidler
AU2001266152A1 (en) Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them
EP1440689A3 (en) Treatment of neurotic disorders
EE04905B1 (et) Pridasino[4,5-b]indool-1-atseetamiidi derivaatide kasutamine ravimite valmistamiseks perifeersete bensodiasepiiniretseptorite dsfunktsioneerimisegaseotud haiguste raviks
NO20023448D0 (no) Medikamentkombinasjon for behandling av depresjon og beslektede forstyrrelser omfattende mirtazapin
ATE286883T1 (de) Isochinolin und chinazolinderivate mit kombinierter 5ht1a, 5ht1b und 5ht1d rezeptor aktivität
AU2002332488A8 (en) R-bambuterol, its preparation and therapeutic uses
AU1546101A (en) Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders
NO20020784L (no) Medikament for behandling av brudd
NO990450L (no) Behandling av sinnslidelser
WO2000061125A3 (fr) L'osanetant dans le traitement des troubles de l'humeur
HK1031101A1 (en) Drug for external use in suffer from traumatic injury, beriberoid disease, lumbago, with its making and magistral medicines
NO20032799L (no) Nye terapeutiske anvendelser av tienylcykloheksylamin- derivater
SE9803276D0 (sv) Use of certain drugs for treating nerve root injury
AU2003209540A1 (en) Topical compostions comprising furfuryl derivatives and their use for the treatment of dermatologic disorders

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application